glp-1 news today november 2025 Receptor Agonists and vision risk President Trump announced the popular

Chronic low-grade inflammation can contribute to multiple cancers, including breast cancer

STEP-HFpEF Trial (NEJM, 2023): 13.3% weight loss plus major improvements in HFpEF symptoms and function

Now a growing number of researchers, payers, and providers are exploring deliberate deprescription, which aims to taper some patients off their medication after they have taken it for a certain amount of time or lost a certain amount of weight

If denied, most state Medicaid programs allow one or two levels of appeal

We should not be screening for thyroid nodules before or during GLP-1 receptor agonist treatment just because the patients are on these medications. Tirzepatide and Severe Side Effects Most of the data shared above was collected from studies of semaglutide and other GLP-1 drugs